Literature DB >> 1702978

Perioperative uses of histamine antagonists.

W Lorenz1, M Ennis, A Doenicke, W Dick.   

Abstract

Histamine release and adverse pseudoallergic/allergic reactions during the perioperative period occur frequently. The incidence of such reactions is 20%-30% for all grades of severity, 1%-5% for systemic reactions, and 0.1%-0.5% for life-threatening reactions. They can be elicited by all commonly used anesthetic agents and by surgical interventions. Both the incidence and severity can be reduced by the use of combined prophylaxis with H1- + H2-receptor antagonists. The authors recommend that this prophylaxis be given to the following groups of patients: those with a history of adverse reactions or history of allergy, patients undergoing surgery with a high risk of histamine release, elderly patients, and those with poor physical status due to underlying systemic diseases. These indications have been developed by heuristic medical decision-making, including a decision tree.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1702978     DOI: 10.1016/0952-8180(90)90083-f

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  4 in total

Review 1.  Anaphylactoid reactions to intravenous solutions used for volume substitution.

Authors:  J Ring
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

2.  Wheal and flare responses to muscle relaxants in humans.

Authors:  J H Levy; D Adelson; B Walker
Journal:  Agents Actions       Date:  1991-11

3.  Models with clinically-relevant and life-threatening histamine-related cardiovascular disturbances: evaluation of the clinical effectiveness of H1/H2-histamine receptor antagonists in perioperative histamine release.

Authors:  M Künneke; B Stinner; D Duda; C Hasse; W Lorenz
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

4.  Open heart surgery increases the levels of histamine in arterial and coronary sinus blood.

Authors:  G Valen; J Kaszaki; S Nagy; J Vaage
Journal:  Agents Actions       Date:  1994-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.